Stocktoria

Silexion Therapeutics Corp SLXN

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-02-17 · LEI

Silexion Therapeutics Corp statistics & valuation

Market cap$2.9M
P / B1.1×
Return on capital-261%
Graham number +2752.9%$12.96

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($12.96); a green figure means the price is below it.

Profitability & efficiency

Gross margin (%)
202320242025
Operating margin (%)
202320242025
Return on equity (%)
-457.60% 202320242025
Shares outstanding
97.1M 8.41B 3.1M 202320242025
Net debt ($)
202320242025
Share buybacks ($)
202320242025
Return on assets (%)
-97.20% -577.00% -165.10% 202320242025
Free cash flow margin (%)
202320242025
Debt / equity (×)
202320242025
EPS ($)
$44.23 $394.94 $8.96 202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023
Return on assets-165.1%-577.0%-97.2%
Return on equity-457.6%414.1%33.0%
Current ratio2.410.642.27

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.